Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection

The continuous evolution of SARS-CoV-2 variants complicates efforts to combat the ongoing pandemic, underscoring the need for a dynamic platform for the rapid development of pan-viral variant therapeutics. Oligonucleotide therapeutics are enhancing the treatment of numerous diseases with unprecedent...

Descripción completa

Detalles Bibliográficos
Autores principales: Hariharan, Vignesh N., Shin, Minwook, Chang, Ching-Wen, O’Reilly, Daniel, Biscans, Annabelle, Yamada, Ken, Guo, Zhiru, Somasundaran, Mohan, Tang, Qi, Monopoli, Kathryn, Krishnamurthy, Pranathi Meda, Devi, Gitali, McHugh, Nicholas, Cooper, David A., Echeverria, Dimas, Cruz, John, Chan, Io Long, Liu, Ping, Lim, Sun-Young, McConnell, Jill, Singh, Satya Prakash, Hildebrand, Samuel, Sousa, Jacquelyn, Davis, Sarah M., Kennedy, Zachary, Ferguson, Chantal, Godinho, Bruno M. D. C., Thillier, Yann, Caiazzi, Jillian, Ly, Socheata, Muhuri, Manish, Kelly, Karen, Humphries, Fiachra, Cousineau, Alyssa, Parsi, Krishna Mohan, Li, Qi, Wang, Yang, Maehr, René, Gao, Guangping, Korkin, Dmitry, McDougall, William M., Finberg, Robert W., Fitzgerald, Katherine A., Wang, Jennifer P., Watts, Jonathan K., Khvorova, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089225/
https://www.ncbi.nlm.nih.gov/pubmed/36893269
http://dx.doi.org/10.1073/pnas.2219523120

Ejemplares similares

Ejemplares similares